DCGI approves emergency use of Zydus’s Virafin

Zydus

Zydus Cadila received emergency use approval from the Drugs Controller General of India (DCGI) for the use of Virafin, Pegylated Interferon alpha- 2b(PegIFN) in treating moderate COVID-19COVID-19 infection in adults. infection in adults. A single dose subcutaneous regimen of the antiviral Virafin will make the treatment more convenient for the patients.  As per the release, Cadila Health highlighted that the drug has also shown efficacy against other viral infections. In its Phase III trial, the therapy has shown better clinical improvements in the patients suffering from COVID-19. 

  • Zydus Cadila received emergency use approval from the Drugs Controller General of India (DCGI) for the use of Virafin, Pegylated Interferon alpha- 2b(PegIFN) in treating moderate COVID-19 infection in adults.

Leave a Reply

Your email address will not be published. Required fields are marked *